Lupin Launches Combination Drug For Patients With Heart Failure Conditions

The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India

Topics

Lupin | Heart Failure  | Heart diseases

Press Trust of India  |  New Delhi 



Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug

Valentas and Arnipin are indicated to reduce repeated hospitalisation and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

Drug maker on Wednesday said it has launched a combination drug for patients with (HF) conditions.

The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India.

In India, HF remains one of the most prevalent causes of death in patients suffering from chronic and the estimated prevalence ranges from 1.3 to 4.6 million, the drug maker said in a statement.

Valentas and Arnipin are indicated to reduce repeated hospitalisation and the risk of cardiovascular death among adult patients with chronic mild to moderate .

"The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy," President - India Region Formulations Rajeev Sibal stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Wed, January 18 2023. 19:14 IST


RECENT NEWS

HSBC Swings The Axe At UK Wealth In An AI Push

HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more

Kraken's Owner Buys A Bank: The Lines Are Blurring

Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more

Revoluts Australian Banking Licence Game Changer

Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more

The AI Bank Is Coming, But Who Controls The Risk?

Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more

ClearBank UK Profit Leads To European Growth

ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more

Bank Of London Continues To Rebuild

ClearBank’s progress shows that modern clearing and banking infrastructure can become a sizeable and profitable busine... Read more